Announcements

Cancers (ISSN: 2072-6694) is an open access journal, thus granting our readers free and unlimited access to the full text of all articles. We welcome you to read our selected papers related to clinical research of cancer in 2024, which are listed below:

1. “Venetoclax Resistance in Acute Myeloid Leukemia”
by Sylvain Garciaz, Marie-Anne Hospital, Yves Collette and Norbert Vey
Cancers 2024, 16(6), 1091; https://doi.org/10.3390/cancers16061091
Available online: https://www.mdpi.com/2072-6694/16/6/1091

2. “Emerging Therapies for Glioblastoma”
by Stella Aimé Rios, Stephanie Oyervides, David Uribe, Angelica Maree Reyes, Victor Fanniel, Jonathan Vazquez and Megan Keniry
Cancers 2024, 16(8), 1485; https://doi.org/10.3390/cancers16081485
Available online: https://www.mdpi.com/2072-6694/16/8/1485

3. “Gastric Cancer: An Up-to-Date Review with New Insights into Early-Onset Gastric Cancer”
by Marek Mazurek, Monika Szewc, Monika Z. Sitarz, Ewa Dudzińska and Robert Sitarz
Cancers 2024, 16(18), 3163; https://doi.org/10.3390/cancers16183163
Available online: https://www.mdpi.com/2072-6694/16/18/3163

4. “Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma”
by Sami Fares, Chase J. Wehrle, Hanna Hong, Keyue Sun, Chunbao Jiao, Mingyi Zhang, Abby Gross, Erlind Allkushi, Melis Uysal, Suneel Kamath et al.
Cancers 2024, 16(8), 1453; https://doi.org/10.3390/cancers16081453
Available online: https://www.mdpi.com/2072-6694/16/8/1453

5. “Inflammation and Related Signaling Pathways in Acute Myeloid Leukemia”
by Nour Sabiha Naji, Mrudula Sathish and Theodoros Karantanos
Cancers 2024, 16(23), 3974; https://doi.org/10.3390/cancers16233974
Available online: https://www.mdpi.com/2072-6694/16/23/3974

6. “Learning Curve for Robotic Colorectal Surgery”
by Neng Wei Wong, Nan Zun Teo and James Chi-Yong Ngu
Cancers 2024, 16(19), 3420; https://doi.org/10.3390/cancers16193420
Available online: https://www.mdpi.com/2072-6694/16/19/3420

7. “Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis”
by Meghana Kesireddy, Lina Elsayed, Valerie K. Shostrom, Priyal Agarwal, Samia Asif, Amulya Yellala and Jairam Krishnamurthy
Cancers 2024, 16(10), 1791; https://doi.org/10.3390/cancers16101791
Available online: https://www.mdpi.com/2072-6694/16/10/1791

8. “Targeted Therapies and Drug Resistance in Advanced Breast Cancer, Alternative Strategies and the Way beyond”
by Andrea Nicolini and Paola Ferrari
Cancers 2024, 16(2), 466; https://doi.org/10.3390/cancers16020466
Available online: https://www.mdpi.com/2072-6694/16/2/466

9. “Deferral of Treatment for Small Choroidal Melanoma and the Risk of Metastasis: An Investigation Using the Liverpool Uveal Melanoma Prognosticator Online (LUMPO)”
by Bertil Damato, Antonio Eleuteri, Azzam Taktak, Rumana Hussain, Maria Fili, Gustav Stålhammar, Heinrich Heimann and Sarah E. Coupland
Cancers 2024, 16(8), 1607; https://doi.org/10.3390/cancers16081607
Available online: https://www.mdpi.com/2072-6694/16/8/1607

10. “Diffuse-Type Tenosynovial Giant Cell Tumor: What Are the Important Findings on the Initial and Follow-Up MRI?”
by Woo Suk Choi, Seul Ki Lee, Jee-Young Kim and Yuri Kim
Cancers 2024, 16(2), 402; https://doi.org/10.3390/cancers16020402
Available online: https://www.mdpi.com/2072-6694/16/2/402

You can view more papers and submit your own manuscript to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

Cancers (ISSN: 2072-6694) is an open access journal, thus granting our readers free and unlimited access to the full text of all articles. We welcome you to read our selected papers related to cancer pathophysiology in 2024, which are listed below:

1. “Application of Nanoparticles for Magnetic Hyperthermia for Cancer Treatment—The Current State of Knowledge”
by Marzena Szwed and Agnieszka Marczak
Cancers 2024, 16(6), 1156; https://doi.org/10.3390/cancers16061156
Available online: https://www.mdpi.com/2072-6694/16/6/1156

2. “The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management”
by Andrea Amaroli, Isabella Panfoli, Matteo Bozzo, Sara Ferrando, Simona Candiani and Silvia Ravera
Cancers 2024, 16(14), 2580; https://doi.org/10.3390/cancers16142580
Available online: https://www.mdpi.com/2072-6694/16/14/2580

3. “Liposarcoma: A Journey into a Rare Tumor’s Epidemiology, Diagnosis, Pathophysiology, and Limitations of Current Therapies”
by Emily Jonczak, Julie Grossman, Francesco Alessandrino, Crystal Seldon Taswell, Jaylou M. Velez-Torres and Jonathan Trent
Cancers 2024, 16(22), 3858; https://doi.org/10.3390/cancers16223858
Available online: https://www.mdpi.com/2072-6694/16/22/3858

4. “Angiogenesis Still Plays a Crucial Role in Human Melanoma Progression”
by Gerardo Cazzato, Giuseppe Ingravallo and Domenico Ribatti
Cancers 2024, 16(10), 1794; https://doi.org/10.3390/cancers16101794
Available online: https://www.mdpi.com/2072-6694/16/10/1794

5. “Clinical Evaluation of the Pancreatic Cancer Microenvironment: Opportunities and Challenges”
by Julianne M. Szczepanski, Mark A. Rudolf and Jiaqi Shi
Cancers 2024, 16(4), 794; https://doi.org/10.3390/cancers16040794
Available online: https://www.mdpi.com/2072-6694/16/4/794

6. “Hereditary Syndromes Associated with Pancreatic and Lung Neuroendocrine Tumors”
by Nektaria Papadopoulou-Marketou, Marina Tsoli, Eleftherios Chatzellis, Krystallenia I. Alexandraki and Gregory Kaltsas
Cancers 2024, 16(11), 2075; https://doi.org/10.3390/cancers16112075
Available online: https://www.mdpi.com/2072-6694/16/11/2075

7. “Soft Tissue Sarcomas with Chromosomal Alterations in the 12q13-15 Region: Differential Diagnosis and Therapeutic Implications”
by Javier Lavernia, Reyes Claramunt, Ignacio Romero, José Antonio López-Guerrero, Antonio Llombart-Bosch and Isidro Machado
Cancers 2024, 16(2), 432; https://doi.org/10.3390/cancers16020432
Available online: https://www.mdpi.com/2072-6694/16/2/432

8. “A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL)”
by Natividad Martínez-Banaclocha, Francisca Martínez-Madueño, Berta Caballé, Joan Badia, Mar Blanes, David Aguiar Bujanda, Virginia Calvo, Jose Gómez Codina, Cristina Quero Blanco, Pablo Espinosa et al.
Cancers 2024, 16(5), 1034; https://doi.org/10.3390/cancers16051034
Available online: https://www.mdpi.com/2072-6694/16/5/1034

9. “Emerging Lipid Targets in Glioblastoma”
by Ammar Darwish, Milán Pammer, Ferenc Gallyas, Jr., László Vígh, Zsolt Balogi and Kata Juhász
Cancers 2024, 16(2), 397; https://doi.org/10.3390/cancers16020397
Available online: https://www.mdpi.com/2072-6694/16/2/397

10. “Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment”
by Nikolaos Vitorakis, Antonios N. Gargalionis, Kostas A. Papavassiliou, Christos Adamopoulos and Athanasios G. Papavassiliou
Cancers 2024, 16(16), 2876; https://doi.org/10.3390/cancers16162876
Available online: https://www.mdpi.com/2072-6694/16/16/2876

You can view more papers and submit your own manuscript to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

September is designated as Prostate Cancer Awareness Month, with various global activities that highlight and increase awareness of prostate cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of prostate cancer, published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field.

The list of relevant papers can be seen below:

“Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer”
by Qiao-Hong Chen, Erick Munoz and Dennis Ashong
Cancers 2024, 16(3), 663; https://doi.org/10.3390/cancers16030663
Available online: https://www.mdpi.com/2072-6694/16/3/663

“Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review”
by Shigekatsu Maekawa, Ryo Takata and Wataru Obara
Cancers 2024, 16(3), 523; https://doi.org/10.3390/cancers16030523
Available online: https://www.mdpi.com/2072-6694/16/3/523

“Emerging Trends in AI and Radiomics for Bladder, Kidney, and Prostate Cancer: A Critical Review”
by Georgios Feretzakis, Patrick Juliebø-Jones, Arman Tsaturyan, Tarik Emre Sener, Vassilios S. Verykios, Dimitrios Karapiperis, Themistoklis Bellos, Stamatios Katsimperis, Panagiotis Angelopoulos, Ioannis Varkarakis et al.
Cancers 2024, 16(4), 810; https://doi.org/10.3390/cancers16040810
Available online: https://www.mdpi.com/2072-6694/16/4/810

“Robot-Assisted Radical Prostatectomy by the Hugo Robotic-Assisted Surgery (RAS) System and the da Vinci System: A Comparison between the Two Platforms”
by Hsien-Che Ou, Lucian Marian, Ching-Chia Li, Yung-Shun Juan, Min-Che Tung, Hung-Jen Shih, Chin-Po Chang, Jian-Ting Chen, Che-Hsueh Yang and Yen-Chuan Ou
Cancers 2024, 16(6), 1207; https://doi.org/10.3390/cancers16061207
Available online: https://www.mdpi.com/2072-6694/16/6/1207

“Robot-Assisted Radical Prostatectomy Performed with the Novel Surgical Robotic Platform Hugo™ RAS: Monocentric First Series of 132 Cases Reporting Surgical, and Early Functional and Oncological Outcomes at a Tertiary Referral Robotic Center”
by Angelo Totaro, Eros Scarciglia, Filippo Marino, Marco Campetella, Carlo Gandi, Mauro Ragonese, Riccardo Bientinesi, Giuseppe Palermo, Francesco Pio Bizzarri, Antonio Cretì et al.
Cancers 2024, 16(8), 1602; https://doi.org/10.3390/cancers16081602
Available online: https://www.mdpi.com/2072-6694/16/8/1602

“Transperineal Laser Ablation (TPLA) Treatment of Focal Low–Intermediate Risk Prostate Cancer”
by Gugliemo Manenti, Tommaso Perretta, Marco Nezzo, Federico Romeo Fraioli, Beatrice Carreri, Paola Elda Gigliotti, Andrea Micillo, Andrea Malizia, Daniele Di Giovanni, Colleen Patricia Ryan et al.
Cancers 2024, 16(7), 1404; https://doi.org/10.3390/cancers16071404
Available online: https://www.mdpi.com/2072-6694/16/7/1404

“From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist’s Dual Role in Prostate Cancer”
by Abdulrahman Alhajahjeh, Raad Al-Faouri, Hisham F. Bahmad, Taima’ Bader, Ryan W. Dobbs, Ahmed A. Abdulelah, Wassim Abou-Kheir, Elai Davicioni, David I. Lee and Mohammed Shahait
Cancers 2024, 16(8), 1538; https://doi.org/10.3390/cancers16081538
Available online: https://www.mdpi.com/2072-6694/16/8/1538

“Glutamine Metabolism and Prostate Cancer”
by Holger H. H. Erb, Nikita Polishchuk, Oleh Stasyk, Uğur Kahya, Matthias M. Weigel and Anna Dubrovska
Cancers 2024, 16(16), 2871; https://doi.org/10.3390/cancers16162871
Available online: https://www.mdpi.com/2072-6694/16/16/2871

“Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review”
by José Pedro Sequeira, Sofia Salta, Rui Freitas, Rafael López-López, Ángel Díaz-Lagares, Rui Henrique and Carmen Jerónimo
Cancers 2024, 16(7), 1363; https://doi.org/10.3390/cancers16071363
Available online: https://www.mdpi.com/2072-6694/16/7/1363

“From Despair to Hope: First Arabic Experience of ¹⁷⁷Lu-PSMA and ¹⁶¹Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer”
by Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Deya’ Aldeen Sweedat, Stephan Maus, Ula Al-Rasheed, Samer Salah, Fadi Khriesh, Diyaa Juaidi, Dina Abu Dayek, Feras Istatieh et al.
Cancers 2024, 16(11), 1974; https://doi.org/10.3390/cancers16111974
Available online: https://www.mdpi.com/2072-6694/16/11/1974

You are welcome to submit relevant papers to the journal Cancers.

Cancers Editorial Office

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our selected papers related to tumor microenvironment in 2024, which are listed below:

1. “The Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway”
by Vasiliki Zoi, Athanassios P. Kyritsis, Vasiliki Galani, Diamanto Lazari, Chrissa Sioka, Spyridon Voulgaris and Georgios A. Alexiou
Cancers 2024, 16(8), 1554; https://doi.org/10.3390/cancers16081554
Available online: https://www.mdpi.com/2072-6694/16/8/1554

2. “TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications”
by Chuqi Wang, Jordan Yong Ming Tan, Nishtha Chitkara and Shruti Bhatt
Cancers 2024, 16(17), 3069; https://doi.org/10.3390/cancers16173069
Available online: https://www.mdpi.com/2072-6694/16/17/3069

3. “Enhancing Tumor Targeted Therapy: The Role of iRGD Peptide in Advanced Drug Delivery Systems”
by Dragana Nikitovic, Ekaterina Kukovyakina, Aikaterini Berdiaki, Alexandros Tzanakakis, Anna Luss, Elizaveta Vlaskina, Anne Yagolovich, Aristides Tsatsakis and Andrey Kuskov
Cancers 2024, 16(22), 3768; https://doi.org/10.3390/cancers16223768
Available online: https://www.mdpi.com/2072-6694/16/22/3768

4. “Heat Shock Proteins, a Double-Edged Sword: Significance in Cancer Progression, Chemotherapy Resistance and Novel Therapeutic Perspectives”
by Dominika Kunachowicz, Magdalena Król-Kulikowska, Wiktoria Raczycka, Jakub Sleziak, Marta Błażejewska and Julita Kulbacka
Cancers 2024, 16(8), 1500; https://doi.org/10.3390/cancers16081500
Available online: https://www.mdpi.com/2072-6694/16/8/1500

5. “Critical Roles of the Sphingolipid Metabolic Pathway in Liver Regeneration, Hepatocellular Carcinoma Progression and Therapy”
by Hiroyuki Nojima, Hiroaki Shimizu, Takashi Murakami, Kiyohiko Shuto and Keiji Koda
Cancers 2024, 16(5), 850; https://doi.org/10.3390/cancers16050850
Available online: https://www.mdpi.com/2072-6694/16/5/850

6. “CSF-1R in Cancer: More than a Myeloid Cell Receptor”
by Francesca Cersosimo, Silvia Lonardi, Cristina Ulivieri, Paolo Martini, Andrea Morrione, William Vermi, Antonio Giordano and Emanuele Giurisato
Cancers 2024, 16(2), 282; https://doi.org/10.3390/cancers16020282
Available online: https://www.mdpi.com/2072-6694/16/2/282

7. “Tumor-Associated Macrophages as Major Immunosuppressive Cells in the Tumor Microenvironment”
by Anghesom Ghebremedhin, Dipti Athavale, Yanting Zhang, Xiaodan Yao, Curt Balch and Shumei Song
Cancers 2024, 16(19), 3410; https://doi.org/10.3390/cancers16193410
Available online: https://www.mdpi.com/2072-6694/16/19/3410

8. “Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells”
by Peter Wai Tik Lee, Lina Rochelle Koseki, Takao Haitani, Hiroshi Harada and Minoru Kobayashi
Cancers 2024, 16(9), 1729; https://doi.org/10.3390/cancers16091729
Available online: https://www.mdpi.com/2072-6694/16/9/1729

9. “HuR (ELAVL1) Stabilizes SOX9 mRNA and Promotes Migration and Invasion in Breast Cancer Cells”
by Jesús Morillo-Bernal, Patricia Pizarro-García, Gema Moreno-Bueno, Amparo Cano, María J. Mazón, Pilar Eraso and Francisco Portillo
Cancers 2024, 16(2), 384; https://doi.org/10.3390/cancers16020384
Available online: https://www.mdpi.com/2072-6694/16/2/384

10. “Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer”
by Keila S. Espinoza and Ashley J. Snider
Cancers 2024, 16(4), 789; https://doi.org/10.3390/cancers16040789
Available online: https://www.mdpi.com/2072-6694/16/4/789

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our selected papers related to infectious agents and cancer in 2024, which are listed below:

1. “Cancer and HIV: The Molecular Mechanisms of the Deadly Duo”
by Aadilah Omar, Natasia Marques and Nicole Crawford
Cancers 2024, 16(3), 546; https://doi.org/10.3390/cancers16030546
Available online: https://www.mdpi.com/2072-6694/16/3/546

2. “Safety, Efficacy, and Immunogenicity of Therapeutic Vaccines for Patients with High-Grade Cervical Intraepithelial Neoplasia (CIN 2/3) Associated with Human Papillomavirus: A Systematic Review”
by Caroline Amélia Gonçalves, Gabriela Pereira-da-Silva, Renata Cristina Campos Pereira Silveira, Paulo César Morales Mayer, Adriana Zilly and Luís Carlos Lopes-Júnior
Cancers 2024, 16(3), 672; https://doi.org/10.3390/cancers16030672
Available online: https://www.mdpi.com/2072-6694/16/3/672

3. “Precision Medicine for Nasopharyngeal Cancer—A Review of Current Prognostic Strategies”
by Luvita Suryani, Hazel P. Y. Lee, Wei Keat Teo, Zhi Kang Chin, Kwok Seng Loh and Joshua K. Tay
Cancers 2024, 16(5), 918; https://doi.org/10.3390/cancers16050918
Available online: https://www.mdpi.com/2072-6694/16/5/918

4. “Activation of Epstein–Barr Virus’ Lytic Cycle in Nasopharyngeal Carcinoma Cells by NEO212, a Conjugate of Perillyl Alcohol and Temozolomide”
by Hannah Hartman-Houstman, Steve Swenson, Radu O. Minea, Uttam K. Sinha, Ming-Fu Chiang, Thomas C. Chen and Axel H. Schönthal
Cancers 2024, 16(5), 936; https://doi.org/10.3390/cancers16050936
Available online: https://www.mdpi.com/2072-6694/16/5/936

5. “Epigenetic Mechanisms in Latent Epstein-Barr Virus Infection and Associated Cancers”
by Atharva S. Torne and Erle S. Robertson
Cancers 2024, 16(5), 991; https://doi.org/10.3390/cancers16050991
Available online: https://www.mdpi.com/2072-6694/16/5/991

6. “Long-Term Survival Rates and Treatment Trends of Burkitt Lymphoma in Patients with HIV—A National Cancer Database (NCDB) Study”
by Clare M. Wieland, Ashley M. Tuin, Elizabeth J. Dort, Alexander G. Hall, Mridula Krishnan and Manasa Velagapudi
Cancers 2024, 16(7), 1397; https://doi.org/10.3390/cancers16071397
Available online: https://www.mdpi.com/2072-6694/16/7/1397

7. “PAX1/JAM3 Methylation and HPV Viral Load in Women with Persistent HPV Infection”
by Mingzhu Li, Chao Zhao, Xiaobo Zhang, Jingran Li, Yun Zhao, Wei Zhang, Lihua Ren and Lihui Wei
Cancers 2024, 16(7), 1430; https://doi.org/10.3390/cancers16071430
Available online: https://www.mdpi.com/2072-6694/16/7/1430

8. “Hepatitis-C-Related Hepatocellular Carcinoma, Still a Relevant Etiology beyond a Hepatitis C Infection Cure”
by Elena Vargas-Accarino, Mónica Higuera, María Buti and Beatriz Mínguez
Cancers 2024, 16(8), 1521; https://doi.org/10.3390/cancers16081521
Available online: https://www.mdpi.com/2072-6694/16/8/1521

9. “HPV DNA Integration at Actionable Cancer-Related Genes Loci in HPV-Associated Carcinomas”
by Xavier Sastre-Garau, Lilia Estrada-Virrueta and François Radvanyi
Cancers 2024, 16(8), 1584; https://doi.org/10.3390/cancers16081584
Available online: https://www.mdpi.com/2072-6694/16/8/1584

10. “Seroprevalence of SARS-CoV-2 and Hepatitis B Virus Coinfections among Ethiopians with Acute Leukemia”
by Jemal Alemu, Balako Gumi, Aster Tsegaye, Ziyada Rahimeto, Dessalegn Fentahun, Fozia Ibrahim, Abdulaziz Abubeker, Amha Gebremedhin, Tesfaye Gelanew and Rawleigh Howe
Cancers 2024, 16(8), 1606; https://doi.org/10.3390/cancers16081606
Available online: https://www.mdpi.com/2072-6694/16/8/1606

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our selected papers related to cancer causes, screening and diagnosis in 2024, which are listed below:

1. “Risk Factors and Innovations in Risk Assessment for Melanoma, Basal Cell Carcinoma, and Squamous Cell Carcinoma”
by K. Wunderlich, M. Suppa, S. Gandini, J. Lipski, J. M. White and V. Del Marmol
Cancers 2024, 16(5), 1016; https://doi.org/10.3390/cancers16051016
Available online: https://www.mdpi.com/2072-6694/16/5/1016

2. “Emerging Trends in AI and Radiomics for Bladder, Kidney, and Prostate Cancer: A Critical Review”
by Georgios Feretzakis, Patrick Juliebø-Jones, Arman Tsaturyan, Tarik Emre Sener, Vassilios S. Verykios, Dimitrios Karapiperis, Themistoklis Bellos, Stamatios Katsimperis, Panagiotis Angelopoulos, Ioannis Varkarakis et al.
Cancers, 2024, 16(4), 810; https://doi.org/10.3390/cancers16040810
Available online: https://www.mdpi.com/2072-6694/16/4/810

3. “Novelty Classification Model Use in Reinforcement Learning for Cervical Cancer”
by Shakhnoza Muksimova, Sabina Umirzakova, Khusanboy Shoraimov, Jushkin Baltayev and Young-Im Cho
Cancers 2024, 16(22), 3782; https://doi.org/10.3390/cancers16223782
Available online: https://www.mdpi.com/2072-6694/16/22/3782

4. “Exploring the Potential Link between PFAS Exposure and Endometrial Cancer: A Review of Environmental and Sociodemographic Factors”
by Aderonke Ayodele and Emmanuel Obeng-Gyasi
Cancers 2024, 16(5), 983; https://doi.org/10.3390/cancers16050983
Available online: https://www.mdpi.com/2072-6694/16/5/983

5. “Imaging Recommendations for Diagnosis and Management of Primary Parathyroid Pathologies: A Comprehensive Review”
by Nivedita Chakrabarty, Abhishek Mahajan, Sandip Basu and Anil K. D’Cruz
Cancers 2024, 16(14), 2593; https://doi.org/10.3390/cancers16142593
Available online: https://www.mdpi.com/2072-6694/16/14/2593

6. “The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)”
by Daniela Fischerova, Filip Frühauf, Andrea Burgetova, Ingfrid S. Haldorsen, Elena Gatti and David Cibula
Cancers 2024, 16(4), 775; https://doi.org/10.3390/cancers16040775
Available online: https://www.mdpi.com/2072-6694/16/4/775

7. “Endometrial Cancer: 2023 Revised FIGO Staging System and the Role of Imaging”
by Manuel Menendez-Santos, Carlos Gonzalez-Baerga, Daoud Taher, Rebecca Waters, Mayur Virarkar and Priya Bhosale
Cancers 2024, 16(10), 1869; https://doi.org/10.3390/cancers16101869
Available online: https://www.mdpi.com/2072-6694/16/10/1869

8. “Non-Invasive Markers for the Detection of Gastric Precancerous Conditions”
by Marcin Romańczyk, Malgorzata Osmola, Alexander Link, Amaury Druet, Caroline Hémont, Jerome Martin, Nicolas Chapelle and Tamara Matysiak-Budnik
Cancers 2024, 16(12), 2254; https://doi.org/10.3390/cancers16122254
Available online: https://www.mdpi.com/2072-6694/16/12/2254

9. “Artificial-Intelligence-Assisted Detection of Metastatic Colorectal Cancer Cells in Ascitic Fluid”
by Hyung Kyung Kim, Eunkyung Han, Jeonghyo Lee, Kwangil Yim, Jamshid Abdul-Ghafar, Kyung Jin Seo, Jang Won Seo, Gyungyub Gong, Nam Hoon Cho, Milim Kim et al.
Cancers 2024, 16(5), 1064; https://doi.org/10.3390/cancers16051064
Available online: https://www.mdpi.com/2072-6694/16/5/1064

10. “Artificial Intelligence in Urologic Robotic Oncologic Surgery: A Narrative Review”
by Themistoklis Bellos, Ioannis Manolitsis, Stamatios Katsimperis, Patrick Juliebø-Jones, Georgios Feretzakis, Iraklis Mitsogiannis, Ioannis Varkarakis, Bhaskar K. Somani and Lazaros Tzelves
Cancers 2024, 16(9), 1775; https://doi.org/10.3390/cancers16091775
Available online: https://www.mdpi.com/2072-6694/16/9/1775

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

At MDPI, we recognize that peer review is the cornerstone of scientific progress. The integrity and quality of our journals rely on the careful evaluations of our reviewers. In 2024, more than 215,000 reviewers submitted over 1.2 million reports—a testament to the strength of our community.

The MDPI Reviewer Club series was created to honor this vital work and provide a forum for sharing experiences, best practices, and building meaningful connections across disciplines.

We are delighted to invite you to the upcoming webinar: “MDPI Reviewer Club 2025 | Public Health and Medicine Session”.

This session is dedicated to bringing together reviewers in the subjects of public health and medicine to exchange insights and celebrate their role in advancing scholarly publishing.

Session highlights:

• From Bench to Publication: Strengthening Biological Science Manuscripts Through Peer Review;
• The Role of Peer Review in Nursing Science: Elevating Manuscript Quality Through Critical Insight.

With speakers’ consent, presentations will be recorded and shared on MDPI platforms to encourage continued discussion.

This marks the only session of the MDPI Reviewer Club 2025 in the subjects of public health and medicine. Each session offers fresh perspectives, cross-disciplinary learning, and a platform to celebrate our reviewers’ invaluable contributions.

We warmly welcome you to join us for this inspiring exchange at the MDPI Reviewer Club 2025 | Public Health and Medicine Session.

Keywords: peer review; public health; clinical medicine; nursing science; biological sciences; manuscript quality; research integrity; publication process; reviewer insights

Date: 18 September 2025 | 6:30 p.m. CEST | 12:30 p.m. EST |
Webinar ID: 852 6635 8176
Website: https://sciforum.net/event/MRC2025-PHM

Register now for free!

Program:

After registering, you will receive a confirmation email with information on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.

Unable to attend? Register anyway, and we will let you know when the recording is available for viewing.

Webinar Speakers:

• Subhadeep Das, Department of Biochemistry, Purdue University, Indiana, USA;
• Wendy L. Sarver, Interim Graduate Program Coordinator, Cleveland State University, Cleveland, USA.

Coinciding with the announcement of the 2025 Nobel Prize in physiology or medicine, this forum underscores the importance of recognizing outstanding achievements that push the boundaries of human knowledge and understanding. It represents a valuable opportunity to exchange ideas on the advancements driving scientific progress and to inspire the next generation of gifted scientists.

General topics of discussion for this event will include the following:

• Breakthrough research shaping the future of physiology or medicine;
• Reflecting on past Nobel Prize-winning work and its legacy;
• The key trends driving innovation in physiology or medicine today;
• Exploring the societal and scientific contributions of physiology or medicine research.

Date: 6 October 2025
Time: 3:30 p.m. CEST | 9:30 a.m. EDT | 9:30 p.m. CST (Asia)
Webinar ID: 852 3554 5031

Register now for free! 

After registering, you will receive a confirmation email with information on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.

Unable to attend? Please register anyway; the session will be recorded, and we will let you know when the recording is available for viewing.

Program:

Webinar Keynote Speakers:

• Prof. Dr. Jacek Z. Kubiak, CNRS/University Rennes UMR 6290, Institute of Genetics and Development of Rennes (IGDR), Rennes, France;
• Prof. Dr Carlos S. Moreno, Department of Pathology & Laboratory Medicine, Department of Biomedical Informatics, Department of Urology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA;
• Prof. Dr Claus Jacob, Division of Bioorganic Chemistry, School of Pharmacy, University of Saarland, Saarland, Germany.

For more information about this webinar, please visit the following link: https://sciforum.net/event/NPR2025PM.

If you have any questions about this webinar, please contact webinar@mdpi.com.

MDPI Webinar Secretariat

We congratulate Dr. Luca Tiraboschi for winning the Cancers 2025 Best PhD Thesis Award with his publication, “Impact of Intratumoral Microbiota in Soft Tissue Sarcoma Treatment Efficacy”. 

Name: Dr. Luca Tiraboschi
Affiliation: IRCCS Humanitas Research Hospital, 20089 Milan, Italy
Research interests: translational research; osteosarcoma; dog; cancer vaccine 

The following is an interview with Dr. Luca Tiraboschi: 

1. Could you tell us a little bit about yourself and the scientific research you conducted during your doctoral studies?
During my PhD, I focused on exploring the interactions between cancer and microbiota. My thesis included two main projects. The first investigated the role of the intratumoral microbiome in soft tissue sarcomas and its ability to inactivate the chemotherapeutic drug doxorubicin, potentially contributing to treatment resistance. The second project aimed to develop an innovative antitumor vaccine based on ER stress-derived peptides, designed to enhance the immune response and possibly overcome resistance to immune checkpoint inhibitors. Overall, my doctoral work combined microbiology, immunology, and oncology, with the broader goal of identifying novel therapeutic strategies for cancer patients. 

2. Did you encounter any difficulties in carrying out this research? If yes, how did you overcome them, and what strategies did you use to stay focused and motivated?
Like most research projects, mine came with challenges both technical and conceptual. Isolating and characterizing tumor-resident bacteria, for example, required the optimization of protocols that were not well established in the field. At times, progress was slower than expected, which was frustrating. What helped me was keeping a clear long-term vision, breaking down big goals into smaller, achievable steps, and relying on the support of my colleagues and mentors. Staying motivated also meant reminding myself of the potential impact my research could have on patients’ lives, which kept me focused during difficult moments. 

3. As an author, what aspects of a journal do you value the most when choosing a journal in which to publish your academic work?
When selecting a journal, I value scientific rigor, transparency in the peer-review process, and a readership that aligns with the scope of my research. I also appreciate journals that foster open access and broad dissemination, making scientific discoveries more widely available to both researchers and clinicians. Additionally, a constructive and fair review process is crucial, as it contributes to improving the quality and clarity of the final manuscript. 

4. What is your current research interest, and how do you plan to continue building on your research in the future? What are your long-term career aspirations?
Currently, I am continuing to investigate the role of the tumor-associated microbiome in modulating the efficacy of cancer therapies, with a focus on chemotherapy and immunotherapy. I aim to integrate microbiology, genomics, and immunology to identify microbiome-based biomarkers and therapeutic strategies that could be translated into clinical applications. In the long term, my aspiration is to build an independent research program at the intersection of oncology and microbiome science, contributing to precision medicine approaches that improve treatment outcomes for cancer patients. 

We congratulate Dr. Filipa Martins for winning the Cancers 2025 Best PhD Thesis Award with her publication, “Targeting Glutamine Availability – A New Strategy To Treat Malignant Gliomas”.

Name: Dr. Filipa Martins
Affiliation: iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal
Research interests: malignant gliomas; glutamine-glutamate cycle; CNS; cancer metabolism; metabolic adaptation; new metabolic-driven targets; neo-angiogenesis; anti-angiogenic therapy; Cancer Therapy; VEGF; new targets; drug resistance

The following is an interview with Dr. Filipa Martins:

1. Could you tell us a little bit about yourself and the scientific research you conducted during your doctoral studies?

I have always been fascinated by the biology of cancer, and my academic background in biochemistry and molecular biology naturally led me to pursue a PhD in health sciences. Previously, I investigated cancer-associated angiogenesis and oxidative stress, but during my doctoral studies, my focus shifted towards cancer metabolism.

My PhD research centered on understanding how glioblastoma (GBM) cells reprogram their metabolic pathways to sustain growth. In particular, we explored the glutamine dependency of GBM, given the altered metabolic networks and preferential carbon source utilization observed in these cells. Based on these insights, we developed two glutamine metabolism-targeted therapies for GBM: a systemic glutaminase (GLS1) treatment that offers a non-invasive approach and avoids the complexities of the blood–brain barrier (BBB) penetration, validated both in vitro and in vivo; and a nanoparticle-based approach with GLS1-targeting dendriplexes (polyurea dendrimers) that cross the BBB and provide a targeted strategy to directly impair metabolic pathways within GBM cells.

These approaches offer a novel and promising direction for GBM therapy, proving that taking advantage of metabolic vulnerabilities favors the development of new therapeutic strategies for GBM. This thesis also emphasizes the importance of personalized metabolic profiling and metabolism-targeted interventions to enhance clinical outcomes.

2. Did you encounter any difficulties in carrying out this research? If yes, how did you overcome them, and what strategies did you use to stay focused and motivated?

Yes, I encountered several challenges during my PhD, as is natural in a multidisciplinary project like this. Right in the beginning, there were a lot of restrictions because of the COVID-19 pandemic, which limited the hours in the lab.

One of the most significant was the development of in vivo models, which was only possible thanks to an excellent collaboration with a research group from ICVS-University of Minho. Moreover, the Pathological Anatomy unit at IPOLisboa was pivotal for histological processing.

Another challenge was handling the vast amount of metabolomics data, which required extensive time and effort to analyze and interpret, done in the CERMAX facilities at ITQB-NOVA. In addition, optimizing the nanoparticles and establishing our in vitro BBB model were technically demanding tasks, but they became feasible through close collaboration with experts from Instituto Superior Técnico and Instituto Ricardo Jorge (INSA).

To overcome these obstacles, we relied on teamwork and adaptability. Collaborating with specialists allowed me to access expertise beyond my own and to learn more in different areas.

The biggest motivator was to contribute to this field and ultimately improve the prognosis and quality of life for patients with this aggressive brain tumor.

3. As an author, what aspects of a journal do you value the most when choosing a journal in which to publish your academic work?

As an author, I value journals that ensure a rigorous yet constructive peer-review process, providing clear and helpful feedback that strengthens the quality of the work. I also appreciate timely responses from the editorial board, as this helps maintain the momentum of the research. Of course, the reputation and integrity of the journal are equally important, as they reflect the credibility of the published work. Visibility within the target research community is another key factor, since dissemination to the right audience maximizes scientific impact. Finally, I take note if the journal is open access, as it promotes accessibility, collaboration, and broader engagement with research findings.

4. What is your current research interest and how do you plan to continue building on your research in the future? What are your long-term career aspirations?

Brain tumors remain one of the most challenging cancers to treat, and I am motivated to contribute to uncovering new biological insights that can be translated into more effective therapies.

In the coming years, I plan to continue brain tumor research through a postdoctoral position. Connecting metabolism, microenvironment and even cancer neuroscience will give us a lot of clues in the following years for more therapeutic vulnerabilities.

5. How does it feel to receive this recognition for your work? Is there something you would like to express or someone you would like to thank the most?

It is with great honor that I receive this award! This recognition holds a very special meaning, especially at such an early stage of my scientific career. It represents not only the acknowledgment of four years of intense work and dedication, but also the validation of the impact and excellence of the research carried out at IPO Lisboa and NOVA Medical School – Faculty of Medical Sciences.

Above all, this award is a reflection of the collective effort of everyone who was part of this project. A very special thank you to my PhD supervisors, Jacinta Serpa, Luís Gonçalves, and Marta Pojo, who guided me through the years. Thank you to the Cancer, Metabolism, and Microenvironment team at IPO Lisboa and NOVA Medical School – Faculty of Medical Sciences, to all my colleagues at UIPM, and to all collaborators who contributed to this work. Many thanks to all of you for being part of this achievement!